These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

677 related articles for article (PubMed ID: 28652891)

  • 21. Non-Alcoholic Fatty Liver Disease, an Overview.
    Nd AM
    Integr Med (Encinitas); 2019 Apr; 18(2):42-49. PubMed ID: 31341444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
    Zhou JH; Cai JJ; She ZG; Li HL
    World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. From Non-Alcoholic Fatty Liver to Hepatocellular Carcinoma: A Story of (Mal)Adapted Mitochondria.
    Amorim R; Magalhães CC; Borges F; Oliveira PJ; Teixeira J
    Biology (Basel); 2023 Apr; 12(4):. PubMed ID: 37106795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatocellular Carcinoma in Non Alcoholic Fatty Liver Disease.
    Tovoli F; Ferri S; Piscaglia F
    Curr Pharm Des; 2020; 26(32):3909-3914. PubMed ID: 32348210
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liver transplantation and non-alcoholic fatty liver disease.
    Zezos P; Renner EL
    World J Gastroenterol; 2014 Nov; 20(42):15532-8. PubMed ID: 25400437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-invasive diagnosis and staging of non-alcoholic fatty liver disease.
    Kechagias S; Ekstedt M; Simonsson C; Nasr P
    Hormones (Athens); 2022 Sep; 21(3):349-368. PubMed ID: 35661987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research.
    Berardo C; Di Pasqua LG; Cagna M; Richelmi P; Vairetti M; Ferrigno A
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348908
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention.
    Tacke F; Weiskirchen R
    Ann Transl Med; 2021 Apr; 9(8):729. PubMed ID: 33987427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss.
    Pouwels S; Sakran N; Graham Y; Leal A; Pintar T; Yang W; Kassir R; Singhal R; Mahawar K; Ramnarain D
    BMC Endocr Disord; 2022 Mar; 22(1):63. PubMed ID: 35287643
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of nonalcoholic fatty liver disease (NAFLD) in severe obesity using noninvasive tests and imaging techniques.
    Theel W; Boxma-de Klerk BM; Dirksmeier-Harinck F; van Rossum EFC; Kanhai DA; Apers J; van Dalen BM; de Knegt RJ; Holleboom AG; Tushuizen ME; Grobbee DE; Wiebolt J; Castro Cabezas M
    Obes Rev; 2022 Aug; 23(8):e13481. PubMed ID: 35692179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical approaches to non-alcoholic fatty liver disease.
    Schwenger KJ; Allard JP
    World J Gastroenterol; 2014 Feb; 20(7):1712-23. PubMed ID: 24587650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
    Estes C; Anstee QM; Arias-Loste MT; Bantel H; Bellentani S; Caballeria J; Colombo M; Craxi A; Crespo J; Day CP; Eguchi Y; Geier A; Kondili LA; Kroy DC; Lazarus JV; Loomba R; Manns MP; Marchesini G; Nakajima A; Negro F; Petta S; Ratziu V; Romero-Gomez M; Sanyal A; Schattenberg JM; Tacke F; Tanaka J; Trautwein C; Wei L; Zeuzem S; Razavi H
    J Hepatol; 2018 Oct; 69(4):896-904. PubMed ID: 29886156
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Non-alcoholic fatty liver disease--new view].
    Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
    Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-alcoholic fatty liver disease in 2015.
    Ahmed M
    World J Hepatol; 2015 Jun; 7(11):1450-9. PubMed ID: 26085906
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunological and molecular basis of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease.
    Radwan MM; Radwan BM; Nandipati KC; Hunter WJ; Agrawal DK
    Expert Rev Clin Immunol; 2013 Aug; 9(8):727-38. PubMed ID: 23971751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pediatric non-alcoholic fatty liver disease: an increasing public health issue.
    Berardis S; Sokal E
    Eur J Pediatr; 2014 Feb; 173(2):131-9. PubMed ID: 24068459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Navigating the Link Between Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis and Cardiometabolic Syndrome.
    Gato S; García-Fernández V; Gil-Gómez A; Rojas Á; Montero-Vallejo R; Muñoz-Hernández R; Romero-Gómez M
    Eur Cardiol; 2024; 19():e03. PubMed ID: 38807856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Non-alcoholic fatty liver disease; a full-bodied epidemic].
    Tushuizen ME; Holleboom AG; Koot BGP; Blokzijl H; van Mil SWC; Koek GH
    Ned Tijdschr Geneeskd; 2020 Feb; 164():. PubMed ID: 32267638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Younossi ZM
    Aliment Pharmacol Ther; 2008 Jul; 28(1):2-12. PubMed ID: 18410557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.